Medical, social and economic burden of age-related macular degeneration

This monograph explores the medical, social, and economic burden of age-related macular degeneration (AMD), a leading cause of irreversible vision loss in individuals over 55 years of age. Authored by experts in the field, it provides a comprehensive analysis of the disease's epidemiology, pathophysiology, and the latest therapeutic approaches. The book examines both the dry and wet forms of AMD, discussing their progression, risk factors, and impact on patients' quality of life. It highlights the role of oxidative stress and genetic predisposition in AMD development, as well as current and emerging therapeutic interventions, including anti-VEGF treatments and innovative genetic therapies. Additionally, it addresses the economic implications of AMD, emphasizing the direct and indirect costs of care, loss of productivity, and social challenges faced by patients, such as reduced autonomy and increased dependency. Supported by a thorough review of literature and real-world data, this publication is an invaluable resource for ophthalmologists, researchers, healthcare policymakers, and anyone interested in mitigating the growing impact of AMD on aging populations.